This analysis examines the current position and future outlook for Shire Pharmaceuticals in the ethical pharmaceutical sector. The profile encompasses global and US company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive analysis tool provides continually updated quantitative and qualitative information.

• Find out how Shire plans to maintain its leadership in the ADHD market, despite generic challenges to its key product Adderall XR
• Benchmark Shire's performance against key rivals in the ethical pharmaceutical sector
• Understand the rationale behind Shire's initially underappreciated $1.6 billion acquisition of Transkaryotic Therapies